Ramipril Oral Suspension is indicated for the following:
Treatment of hypertension.
Manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or
Diabetes with at least one cardiovascular risk factor (see section 5.1 on the EMC).
Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria
Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor (see section 5.1 on the EMC)
Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥3 g/day (see section 5.1 on the EMC).
Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.
Summary of Product Characteristics
Read this summary of product characteristics for further information about Ramipril Oral Suspension. Click below to navigate to the EMC.
Patient Information Leaflet
Read this patient information leaflet about Ramipril Oral Suspension, what it’s used for and possible side effects. Click below to navigate to the EMC.
Ramipril Oral Solution
|Click here for Audio Version
|Store in a refrigerator (2-8ºC).
|Shelf Life (Closed Bottle/Open Bottle)
|24 months / 1 month
For further product information and pricing please use the form below and a member of the team will be in touch
Stay updated via our App
A new Rosemont Pharmaceuticals App for Healthcare Professionals is launching soon.